Tricyclic GyrB/ParE (TriBE) inhibitors: A new class of broad-spectrum dual-targeting antibacterial agents

PLoS ONE

Volumn 8, Issue 12, 2013, Pages

  Tari, Leslie W ^a   Li, Xiaoming ^a   Trzoss, Michael ^a   Bensen, Daniel C ^a   Chen, Zhiyong ^a   Lam, Thanh ^a   Zhang, Junhu ^a   Lee, Suk Joong ^a   Hough, Grayson ^a   Phillipson, Doug ^a   Akers Rodriguez, Suzanne ^a   Cunningham, Mark L ^a   Kwan, Bryan P ^a   Nelson, Kirk J ^a   Castellano, Amanda ^a   Locke, Jeff B ^a   Brown Driver, Vickie ^a   Murphy, Timothy M ^b,f   Ong, Voon S ^a   Pillar, Chris M ^c   Shinabarger, Dean L ^c   Nix, Jay ^d   Lightstone, Felice C ^e   Wong, Sergio E ^e   Nguyen, Toan B ^e   Shaw, Karen J ^a   Finn, John ^a   more..

^a Trius Therapeutics   (United States)

^b ViviSource Laboratories   (United States)

^c Micromyx LLC   (United States)

^d LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^e LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

^f UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (6 AMINO 1 METHYL 3 AZABICYCLO[3.2.0]HEPTAN 3 YL) 6 FLUORO N METHYL 2 [(2 METHYLPYRIMIDIN 5 YL)OXY] 9H PYRIMIDO[4,5 B]INDOL 8 AMINE; 6 FLUORO 4 (HEXAHYDROPYRROLO[3,4 B]PYRROL 5(1H) YL) N METHYL 2 [(2 METHYLPYRIMIDIN 5 YL)OXY] 9H PYRIMIDO[4,5 B]INDOL 8 AMINE; AMPICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFUROXIME; CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) B; DNA TOPOISOMERASE INHIBITOR; DNA TOPOISOMERASE IV; GENTAMICIN; IMIPENEM; INDOLE DERIVATIVE; LEVOFLOXACIN; LINEZOLID; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG; VANCOMYCIN;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; ENTEROCOCCUS FAECALIS; ENZYME INHIBITION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FRANCISELLA TULARENSIS; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; GRAM POSITIVE BACTERIUM; HAEMOPHILUS INFLUENZAE; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PSEUDOMONAS AERUGINOSA; SINGLE DRUG DOSE; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIA; DNA GYRASE; DNA TOPOISOMERASE IV; DRUG DESIGN; DRUG RESISTANCE, BACTERIAL; FEMALE; INDOLES; MICE; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; PROTEIN CONFORMATION; TOPOISOMERASE II INHIBITORS;

EID: 84893433328     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0084409     Document Type: Article

References (41)

1. Walsh CT (2003) Where will new antibiotics come from? Nat Rev Microbiol 1: 65-70. doi:10.1038/nrmicro727. PubMed: 15040181.
2. Silver LL (2011) Challenges of antibacterial discovery. Clin Microbiol Rev 24: 71-109. doi:10.1128/CMR.00030-10. PubMed: 21233508.
3. Fischbach MA, Walsh CT (2009) Antibiotics for emerging pathogens. Science. 325: 1089-1093. doi:10.1126/science.1176667. PubMed: 19713519.
4. Sissi C, Palumbo M (2010) In front of and behind the replication fork: bacterial type IIa topoisomerases. Cell Mol Life Sci 67: 2001-2024. doi:10.1007/s00018-010-0299-5. PubMed: 20165898.
5. Collin F, Karkare S, Maxwell A (2011) Exploiting bacterial DNA gyrase as a drug target: current state and perspectives. Appl Microbiol Biotechnol 92: 479-497. doi:10.1007/s00253-011-3557-z. PubMed: 21904817.
6. Hooper DC (2001) Emerging mechanisms of fluoroquinolone resistance. Emerg Infect Dis 7: 337-341. doi:10.3201/eid0702.010239. PubMed: 11294736.
7. Oblak M, Kotnik M, Solmajer T (2007) Discovery and development of ATPase inhibitors of DNA gyrase as antibacterial agents. Curr Med Chem 14: 2033-2047. doi:10.2174/092986707781368414. PubMed: 17691945. (Pubitemid 47578161)
8. Lambert HP, O'Grady FW (1992) Coumarins; HP LambertFW O'Grady. Churchill Livingstone: Edinburgh.
9. Eakin AE, Green O, Hales N, Walkup GK, Bist S et al. (2012) Pyrrolamide DNA gyrase inhibitors: Fragment-based nuclear magnetic resonance screening to identify antibacterial agents. Antimicrob Agents Chemother 56: 1240-1246. doi:10.1128/AAC.05485-11. PubMed: 22183167.
10. Charifson PS, Grillot A-L, Grossman TH, Parsons JD, Badia M et al. (2008) Novel dual-targeting benzimidazole urea inhibitors of DNA gyrase and topoisomerase IV possessing potent antibacterial activity: Intelligent design and evolution through the judicious use of structure-guided design and structure-activity relationships. J Med Chem 51: 5243-5263. doi:10.1021/ jm800318d. PubMed: 18690678.
11. East SP, White CB, Barker O, Barker S, Bennett J et al. (2009) DNA gyrase (GyrB)/topoisomerase IV (ParE) inhibitors: Synthesis and antibacterial activity. Bioorg Med Chem Lett 19: 894-899. doi:10.1016/j.bmcl.2008.11.102. PubMed: 19095445.
12. Sherer BA, Hull K, Green O, Basarab G, Hauck S et al. (2011) Pyrrolamide DNA gyrase inhibitors: Optimization of antibacterial activity and efficacy. Bioorg Med Chem Lett 21: 7416-7420. doi:10.1016/j.bmcl.2011.10.010. PubMed: 22041057.
13. Mani N, Gross CH, Parsons JD, Hanzelka B, Müh U et al. (2006) In vitro characterization of the antibacterial spectrum of novel bacterial type II topoisomerase inhibitors of the aminobenzimidazole class. Antimicrob Agents Chemother 50: 1228-1237. doi:10.1128/AAC.50.4.1228-1237.2006. PubMed: 16569833.
14. Boehm HJ, Boehringer M, Bur D, Gmuender H, Huber W et al. (2000) Novel inhibitors of DNA gyrase: 3D structure biased needle screening hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening. J Med Chem 43: 2664-2674. doi:10.1021/jm000017s. PubMed: 10893304. (Pubitemid 30463915)
15. Tari LW, Trzoss M, Bensen DC, Li X, Chen Z et al. (2013) Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE). Part I: Structure guided discovery and optimization of dual targeting agents with potent, broad-spectrum enzymatic activity. Bioorg Med Chem Lett 23: 1529-1536. doi:10.1016/j.bmcl.2012.11.032. PubMed: 23352267.
16. Trzoss M, Bensen DC, Li X, Chen Z, Lam T et al. (2013) Pyrrolopyrimidine inhibitors of DNA gyrase B (GyrB) and topoisomerase IV (ParE). Part II: Development of inhibitors with broad spectrum, Gram-negative antibacterial activity. Bioorg Med Chem Lett 23: 1537-1543. doi:10.1016/j.bmcl.2012.11.073. PubMed: 23294697.
17. Bellon S, Parsons JD, Wei Y, Hayakawa K, Swenson LL et al. (2004) Crystal structures of Escherichia coli topoisomerase IV ParE subunit (24 and 43 kilodaltons): a single residue dictates differences in novobiocin potency against topoisomerase IV and DNA gyrase. Antimicrob Agents Chemother 48: 1856-1864. doi:10.1128/AAC. 48.5.1856-1864.2004. PubMed: 15105144.
18. Dutta R, Inouye M (2000) GHKL, an emergent ATPase/kinase superfamily. Trends Biochem Sci 25: 24-28. doi:10.1016/S0968-0004(99)01503-0. PubMed: 10637609. (Pubitemid 30060426)
19. Ceccarelli M, Ruggerone P (2008) Physical insights into permeation of and resistance to antibiotics in bacteria. Curr Drug Targets. 9: 779-788. doi:10.2174/138945008785747770. PubMed: 18781923.
20. Nikaido H, Thanassi DG (1993) Penetration of lipophilic agents with multiple protonation sites into bacterial cells: tetracyclines and fluoroquinolones as examples. Antimicrob Agents Chemother 37: 1393-1399. doi:10.1128/AAC.37.7.1393. PubMed: 8363364. (Pubitemid 23202359)
21. Appelbaum PC, Hunter PA (2000) The fluoroquinolone antibacterials: past present and future perspectives. Int Journal Antimicrob Agents. 16: 5-15. doi:10.1016/S0924-8579(00)00192-8. (Pubitemid 30665419)
22. Liao CZ, Nicklaus MC (2009) Comparison of nine programs predicting pK(a) values of pharmaceutical substances. J Chem Inf Model 49: 2801-2812. doi:10.1021/ci900289x. PubMed: 19961204.
23. Grossman TH, Bartels DJ, Mullin S, Gross CH, Parsons JD et al. (2007) Dual targeting of GyrB and ParE by a novel aminobenzimidazole class of antibacterial compounds. Antimicrob Agents Chemother 51: 657-666. doi:10.1128/AAC.00596-06. PubMed: 17116675. (Pubitemid 46185287)
24. Bensen DC, Finn J, Lee SJ, Chen Z, Lam T et al. Tricyclic Gyrase Inhibitors. Int. Pat. Appl. Pub. WO/2012/125746
25. Morrison JF (1969) Kinetics of reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. Biochim Biophys Acta. 185: 269-286. doi:10.1016/0005-2744(69)90420-3. PubMed: 4980133.
26. Cunningham ML, Kwan BP, Nelson KJ, Bensen DC, Shaw KJ (2013) Distinguishing on-target versus off-target activity in early antibacterial drug discovery using a macromolecular synthesis assay. J Biomol Screen 18: 1018-1026. doi:10.1177/1087057113487208. PubMed: 23686103.
27. Leslie AGW (1992) Recent changes to the MOSFLM package for processing film and image plate data. Joint CCP4 + ESF-EAMBC Newsl. Protein Crystallogr. 26.
28. Collaborative Computational Project Number 4 (1994) The CCP4 suite: programmes for protein crystallography. Acta Crystallogr D50: 760-763
29. Pflugrath JW (1999) The finer things in X-ray diffraction data collection. Acta. Crystallogr D55: 1718-1725. PubMed: 10531521.
30. McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC et al. (2007) Phaser crystallographic software. J Appl Crystallography 40: 658-674. doi:10.1107/S0021889807021206. PubMed: 19461840. (Pubitemid 47080256)
31. Murshudov GN, Skubák P, Lebedev AA, Pannu NS, Steiner RA et al. (2011) REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystsllogr D67: 355-367. PubMed: 21460454.
32. Emsley P, Lohkamp B, Scott WG, Cowtan K (2010) Features and development of Coot. Acta Crystallogr D66: 486-501. PubMed: 20383002.
33. Laskowski RA, Macarthur MW, Moss DS, Thornton JM (1993) PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallography 26: 283-291. doi:10.1107/S0021889892009944.
34. Lovell SC, Davis IW, Arendall WB III, de Bakker PI, Word JM et al. (2003) Structure validation by Calpha geometry: phi, psi and Cbeta deviation. Proteins. 50: 437-450. doi:10.1002/prot.10286. PubMed: 12557186.
35. Lafitte D, Lamour V, Tsvetkov PO, Makarov AA, Klich M et al. (2002) DNA gyrase interaction with coumarin-based inhibitors: the role of the hydroxybenzoate isopentenyl moiety and the 5'-methyl group of the noviose. Biochemistry 41: 7217-7223. doi:10.1021/bi0159837. PubMed: 12044152. (Pubitemid 34602437)
36. Hou T, Wang J, Li Y, Wang W (2011) Assessing the performance of the molecular mechanics/Poisson Boltzmann surface area and molecular mechanics/generalized Born surface area methods. II. The accuracy of ranking poses generated from docking. J Comput Chem 32: 866-873. doi:10.1002/jcc.21666. PubMed: 20949517.
37. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ et al. (2004) Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy. J Med Chem 47: 1739-1749. doi:10.1021/jm0306430. PubMed: 15027865. (Pubitemid 38380917)
38. Schrodinger (New York, NY (2011).
39. Case DA, Darden TA, Cheatham III, Simmerling J et al. (University of California - San Francisco, 2008).
40. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK et al. (2009) AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem 30: 2785-2791. doi:10.1002/jcc.21256. PubMed: 19399780.
41. A. S. Inc. (Accelrys Software Inc., San Diego, CA, 2012).